
Global Diabetic Nephropathy Market Outlook to 2022 with AstraZeneca, Merck and Sanofi Dominating - ResearchAndMarkets.com
The "Global Diabetic Nephropathy Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The diabetic nephropathy market will register a CAGR of almost 34% by 2022.
Rise in incidence of diabetes to push growth in the market
Globally, there has been a rise in the incidence and prevalence of diabetes, which has resulted in the occurrence of chronic kidney disease in patients.
Increasing incidence of diabetic nephropathy among diabetic patients
The incidence of diabetic nephropathy was observed to be much higher in freshly diagnosed cases of type 2 diabetes patients. The factors associated with the rise of incidence of nephropathy are hypertension, hypercholesterolemia, and obesity.
Growing economic burden of diabetic nephropathy
Diabetic nephropathy is a complication associated with diabetes mellitus. The cost associated with diabetic nephropathy increases gradually with the progression of disease due to the associated cost drivers such as dialysis and hospitalization.
Key Players
- AstraZeneca
- Merck
- Sanofi
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY DRUG CLASS
- Segmentation by drug class
- Comparison by drug class
- ARBs - Market size and forecast 2017-2022
- ACE inhibitors - Market size and forecast 2017-2022
- Others - Market size and forecast 2017-2022
- Market opportunity by drug class
PART 09: MARKET SEGMENTATION BY TYPE OF DISEASE
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
PART 14: MARKET TRENDS
- Rise in incidence of diabetes
- Increase in diabetic nephropathy-related cardiovascular mortality and end-stage renal disease
- Multidisciplinary approach for the management of diabetic nephropathy
PART 15: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 16: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AstraZeneca
- Merck
- Sanofi
For more information about this report visit https://www.researchandmarkets.com/research/7ccgpp/global_diabetic?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20190108005612/en/
Editor Details
-
Company:
- Business Wire
- Website: